CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- 4 Open-market sale Director sold 150,000 shares at an average $16.24 ($2,435,440)
- 4 Open-market sale 10% owner sold 150,000 shares at an average $16.24 ($2,435,440)
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- S-8 Other Securities Offered to Employees in Benefit Plans
- S-3 Offering Registration Statement
- 4 Grant or award Director acquired 5,000 shares (grant or award)
- 4 Grant or award Director acquired 5,000 shares (grant or award)
- 4 Grant or award EVP, Chief Financial Officer acquired 8,400 shares (grant or award)
- 4 Grant or award EVP, General Counsel & Ops acquired 8,400 shares (grant or award)
- 4 Grant or award EVP, R&D acquired 8,400 shares (grant or award)
- 4 Grant or award President & CEO acquired 8,400 shares (grant or award)
Page 31 of 37 · 725 filings